The 69 references in paper S. Avdeev N., С. Авдеев Н. (2014) “ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ СОВРЕМЕННЫХ МУКОАКТИВНЫХ ПРЕПАРАТОВ В ТЕРАПИИ ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНЬЮ ЛЕГКИХ // PERSPECTIVES OF NOVEL MUCOACTIVE DRUGS IN THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” / spz:neicon:pulmonology:y:2014:i:2:p:100-108

1
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2014. www.goldcopd.org
(check this in PDF content)
2
Celli B.R., MacNee W.; ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.
(check this in PDF content)
3
Barnes P.J., Shapiro S.D., Pauwels R.A.Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir. J. 2003; 22: 672–688.
(check this in PDF content)
4
Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709–721.
(check this in PDF content)
5
Barnes P.J.Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 269–280.
(check this in PDF content)
6
Barnes P.J.Molecular genetics of chronic obstructive pulmonary disease. Thorax. 1999; 54: 245–252.
(check this in PDF content)
7
Meshi B., Vitalis T.Z., Ionescu D. et al.Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am. J. Respir. Cell. Mol. Biol. 2002; 26: 52–57.
(check this in PDF content)
8
Ito K., Barnes P.J., Adcock I.M. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1binduced histone H4 acetylation on lysines 8 and 12. Mol. Cell. Biol. 2000; 20: 6891–6903.
(check this in PDF content)
9
Rutgers S.R., Postma D.S., ten Hacken N.H. et al.Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12–18.
(check this in PDF content)
10
Burgel P.R., Nadel J.A. Epidermal growth factor receptormediated innate immune responses and their roles in airway diseases. Eur. Respir. J. 2008; 32: 1068–1081.
(check this in PDF content)
11
Randell S.H., Boucher R.C.Effective mucus clearance is essential for respiratory health. Am. J. Respir. Cell. Mol. Biol. 2006; 35: 20–28.
(check this in PDF content)
12
Innes A.L., Carrington S.D., Thornton D.J. et al. Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Am. J. Respir. Crit. Care Med. 2009; 180: 203–210.
(check this in PDF content)
13
Rogers D.F., Barnes P.J. Treatment of airway mucus hypersecretion. Ann. Med. 2006; 38: 116–125.
(check this in PDF content)
14
Lethem M.I., James S.L., Marriott C., Burke J.F. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur. Respir. J. 1990; 3: 19–23.
(check this in PDF content)
15
Tomkiewicz R.P., Kishioka C., Freeman J., Rubin B.K. DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum G.L., Priel Z., Roth Y., Liron N., Ostfeld E.J., eds. Cilia, Mucus, and Mucociliary Interactions. New York: Dekker; 1998: 333–341.
(check this in PDF content)
16
Shah S.A., Santago P., Rubin B.K.Quantification of biopolymer filament structure. Ultramicroscopy. 2005; 104: 244–254.
(check this in PDF content)
17
Hogg J.C., Chu F., Utokaparch S. et al.The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645–2653.
(check this in PDF content)
18
James A.L., Wenzel S.Clinical relevance of airway remodelling in airway diseases. Eur. Respir. J. 2007; 30: 134–155.
(check this in PDF content)
19
Macklem P.T., Proctor D.F., Hogg J.C.The stability of peripheral airways. Respir. Physiol. 1970; 8: 191–203.
(check this in PDF content)
20
Hogg J.C., Chu F.S., Tan W.C. et al.Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am. J. Respir. Crit. Care Med. 2007; 176: 454–459.
(check this in PDF content)
21
Openshaw P.J., Turner-Warwick M.Observations on sputum production in patients with variable airflow obstruction; implications for the diagnosis of asthma and chronic bronchitis. Respir. Med. 1989; 83: 25–31.
(check this in PDF content)
22
Turner-Warwick M., Openshaw P. Sputum in asthma. Postgrad. Med. J. 1987; 63 (Suppl. 1): 79–82.
(check this in PDF content)
23
Rogers D.F.Mucoactive agents for airway mucus hypersecretory diseases. Respir. Care. 2007; 52: 1176–1193.
(check this in PDF content)
24
Burgel P.-R., Nesme-Meyer P., Chanez P. et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009; 135: 975–982.
(check this in PDF content)
25
Speizer F.E., Fay M.E., Dockery D.W. et al. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am. Rev. Respir. Dis. 1989; 140 (Suppl. 3): S49–S55.
(check this in PDF content)
26
Prescott E., Lange P., Vestbo J.Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur. Respir. J. 1995; 8: 1333–1338.
(check this in PDF content)
27
Vestbo J., Prescott E., Lange P.Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. J. Respir. Crit. Care Med. 1996; 153: 1530–1535.
(check this in PDF content)
28
Marco R., Accordini S., Cerveri I. et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am. J. Respir. Crit. Care Med. 2007; 175: 32–39.
(check this in PDF content)
29
Kohansal R., Martinez-Camblor P., Agusti A. et al. The natural history of chronic air flow obstruction revisited: an analysis of the Framingham offspring cohort. Am. J. Respir. Crit. Care Med. 2009; 180: 3–10.
(check this in PDF content)
30
Авдеев С.Н. Значение мукоактивных препаратов в терапии хронической обструктивной болезни легких. Пульмонология. 2011; 4: 118–124. / Avdeev S.N. A role of mucoactive drugs in therapy of chronic obstructive pulmonary disease. Pul'monologiya. 2011; 4: 118–124 (in Russian).
(check this in PDF content)
31
Vliet A., O'Neill C.A., Cross C.E. et al. Determination of low-molecular-mass antioxidant concentrations in human respiratory tract lining fluids. Am. J. Physiol. 1999; 276: L289–296.
(check this in PDF content)
32
Rahman I., Adcock I.M. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J. 2006; 28: 219–242.
(check this in PDF content)
33
Ricevuti G., Mazzone A., Uccelli E. et al.Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax. 1988; 43: 585–590.
(check this in PDF content)
34
Moldeus P., Cotgreave I.A., Berggren M.Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration. 1986; 50: 31–42. Авдеев С.Н.Перспективы применения современных мукоактивных препаратов в терапии пациентов с ХОБЛ
(check this in PDF content)
35
Tashkin D.P., Celli B., Senn S. et al.for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.
(check this in PDF content)
36
Moretti M.Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2007; 1 (3): 307–316.
(check this in PDF content)
37
Moretti M.Erdosteine: its relevance in COPD treatment. Expert Opin. Drug Metab. Toxicol. 2009; 5: 333–343.
(check this in PDF content)
38
Savu S., Mitrea M., Silvestro L., Mancini C.HPLC with on-line mass spectrometry detection applicable to elucidate erdosteine metabolism. Int. J. Clin. Pharmacol. Ther. 2000; 38: 415–417.
(check this in PDF content)
39
Marchioni C.F., Moretti M., Muratori M. et al.Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease. Lung 1990; 168: 285–293.
(check this in PDF content)
40
Olivieri D., Del Donno M., Casalini A. et al. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis. Respiration 1991; 58: 91–94.
(check this in PDF content)
41
Hotzinger H. Erdosteine or placebo combined with co-trimoxazole in the treatment of hypersecretive infectious bronchitis. Med. Praxis 1991; 12: 171–181.
(check this in PDF content)
42
Zanasi A., Menarini A. Erdosteine versus N-acetylcysteine in the treatment of exacerbation of chronic bronchopneumopathies. Med. Praxis 1991; 12: 207–217.
(check this in PDF content)
43
Ghiringhelli G. Cross-over study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchial disease in stable hypersecretive phase: Controlled double-blind study vsplacebo. Arch. Med. Inter. 1995; 47: 113–120.
(check this in PDF content)
44
Braga P.C., Dal Sasso M., Sala M.T., Gianelle V.Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittel-Forsch. 1999; 49: 344–350.
(check this in PDF content)
45
Braga P.C. Bacterial adhesion to human cells. In: Edi-Aipo Scientifica 2000: 1–63.
(check this in PDF content)
46
Dal Negro R.W., Visconti M., Micheletto C., Tognella S. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm. Pharmacol. Ther. 2008; 21: 304–308.
(check this in PDF content)
47
Braga P.C.Oxidative stress: respiratory diseases and thiol compounds. Edi-Aipo Scientifica 2006: 1–104.
(check this in PDF content)
48
Miyake K., Kaise T., Hosoe H. et al.The effect of Erdosteine and its active metabolite on reactive oxygen species production by inflammatory cells. Inflam. Res. 1999; 48: 205–209.
(check this in PDF content)
49
Manchini C., Nicola M., Lumachi B.Erdosteine effects on serum malondialdehyde of healthy smokers and non-smokers. A pilot study. Eur. Respir. J. 1997; 10 (Suppl. 25): 95s.
(check this in PDF content)
50
Mitrea M.Reduced (GSH) and oxidized (GSSG) levels in plasma and BAL of chronic bronchitis patients treated with erdosteine or N-acetylcysteine (NAC). In: 6th International Conference on Bronchoalveolar Lavage: Abstracts. Corfu (Greece), June 24–27 1998.
(check this in PDF content)
51
Dal Negro R.W., Visconti M., Tognella S., Micheletto C. Erdosteine affects eicosanoid production in COPD. Int. J. Clin. Pharmacol. Ther. 2011; 49: 41–45.
(check this in PDF content)
52
Malerba M., Ponticiello A., Radaeli A. et al.Effect of twelvemonths therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm. Pharmacol. Ther. 2004; 17: 27–34.
(check this in PDF content)
53
Poole P., Black P.N. Mucolytic agents for chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 19 (3): JulCD001287.
(check this in PDF content)
54
Zheng J.P., Kang J., Huang S.G. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet. 2008; 371: 2013–2018.
(check this in PDF content)
55
Tse H.N., Raiteri L., Wong K.Y. et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013; 144: 106–118.
(check this in PDF content)
56
Zheng J.-P., Wen F.-Q., Bai C.-X. et al., on behalf of the PANTHEON study group. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2: 187–194.
(check this in PDF content)
57
Aubier M., Berdah L.Étude multicentrique, contrôlée, en double aveugle, de l'efficacitéet de la tolérance de Vectrine (erdosteine) versus placebo dans le traitement de la bronchite chronique hypersecretante stabilisee. Rev. Mal. Respir. 1999; 16: 521–528.
(check this in PDF content)
58
Fioretti M., Bandera M. Prevention of exacerbations in chronic bronchitic patients with erdosteine. Med. Praxis. 1991; 12: 219–227.
(check this in PDF content)
59
Moretti M., Bottrighi P., Dallari R. et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: The equalife study. Drugs Exp. Clin. Res. 2004, 30: 143–152.
(check this in PDF content)
60
Stanford R.H., Shen Y., McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat. Respir. Med. 2006; 5: 343–349.
(check this in PDF content)
61
O'Donnell D.E., Parker C.M. COPD exacerbations: Pathophysiology. Thorax. 2006; 61: 354–361.
(check this in PDF content)
62
Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57: 847–852.
(check this in PDF content)
63
Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 151: 1418–1422.
(check this in PDF content)
64
Miravitlles M., Murio C., Guerrero T. et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449–1455.
(check this in PDF content)
65
Zuin R., Palamidese A., Negrin R. et al.High dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin. Drug Invest. 2005; 25: 401–408.
(check this in PDF content)
66
Marchioni C.F., Polu J.M., Taytard A. et al.Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharmacol. Ther. 1995; 33: 612–618.
(check this in PDF content)
67
Mohanty K.C., Thiappanna G., Singh V., Mancini C.Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment. J. Clin. Res. 2001; 4: 35–39.
(check this in PDF content)
68
Bisetti A., Mancini C. Mucolytic activity of erdosteine double blind clinical trial vsplacebo. Arch. Med. Inter. 1995; 47: 89–97.
(check this in PDF content)
69
Bianchi B., Ballabio M., Moretti M.Effects of erdosteine on serum biomarker concentrations at COPD exacerbation. Eur. Respir. J. 2010; 36 (Suppl.): 378. Информация об авторах Авдеев Сергей Николаевич– д. м. н., профессор, руководитель клини-
(check this in PDF content)